Global CINV Existing and Pipeline Drugs market is expected to grow from US$ 1676 million in 2025 to US$ 2038 million in 2031; it is expected to grow at a CAGR of 3.3% from 2025 to 2031.

Global CINV Existing and Pipeline Drugs Market Size and Outlook 2025-31

The global CINV Existing and Pipeline Drugs market size is predicted to grow from US$ 1676 million in 2025 to US$ 2038 million in 2031; it is expected to grow at a CAGR of 3.3% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the CINV Existing and Pipeline Drugs Industry Forecast looks at past sales and reviews total world CINV Existing and Pipeline Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected CINV Existing and Pipeline Drugs sales for 2025 through 2031. With CINV Existing and Pipeline Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CINV Existing and Pipeline Drugs industry. This Insight Report provides a comprehensive analysis of the global CINV Existing and Pipeline Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CINV Existing and Pipeline Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global CINV Existing and Pipeline Drugs market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CINV Existing and Pipeline Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CINV Existing and Pipeline Drugs. This report presents a comprehensive overview, market shares, and growth opportunities of CINV Existing and Pipeline Drugs market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Aloxi &nbsp;&nbsp;&nbsp; Zofran Generic &nbsp;&nbsp;&nbsp; Kytril Generic &nbsp;&nbsp;&nbsp; Emend &nbsp;&nbsp;&nbsp; Akynzeo &nbsp;&nbsp;&nbsp; SUSTOL &nbsp;&nbsp;&nbsp; Rolapitant Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Specialty Clinics &nbsp;&nbsp;&nbsp; Diagnostic Centers Therapeutics &nbsp;&nbsp;&nbsp; Hospital Pharmacies &nbsp;&nbsp;&nbsp; Drugstores This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GlaxoSmithKline &nbsp;&nbsp;&nbsp; Helsinn &nbsp;&nbsp;&nbsp; Heron Therapeutics &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Tesaro Key Questions Addressed in this Report What is the 10-year outlook for the global CINV Existing and Pipeline Drugs market? What factors are driving CINV Existing and Pipeline Drugs market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do CINV Existing and Pipeline Drugs market opportunities vary by end market size? How does CINV Existing and Pipeline Drugs break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global CINV Existing and Pipeline Drugs Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 CINV Existing and Pipeline Drugs Segment by Type &nbsp;2.2.1 Aloxi &nbsp;2.2.2 Zofran Generic &nbsp;2.2.3 Kytril Generic &nbsp;2.2.4 Emend &nbsp;2.2.5 Akynzeo &nbsp;2.2.6 SUSTOL &nbsp;2.2.7 Rolapitant &nbsp;2.3 CINV Existing and Pipeline Drugs Sales by Type &nbsp;2.3.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global CINV Existing and Pipeline Drugs Sale Price by Type (2020-2025) &nbsp;2.4 CINV Existing and Pipeline Drugs Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Specialty Clinics &nbsp;2.4.3 Diagnostic Centers Therapeutics &nbsp;2.4.4 Hospital Pharmacies &nbsp;2.4.5 Drugstores &nbsp;2.5 CINV Existing and Pipeline Drugs Sales by Application &nbsp;2.5.1 Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global CINV Existing and Pipeline Drugs Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global CINV Existing and Pipeline Drugs Breakdown Data by Company &nbsp;3.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2020-2025) &nbsp;3.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Company (2020-2025) &nbsp;3.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global CINV Existing and Pipeline Drugs Sale Price by Company &nbsp;3.4 Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers CINV Existing and Pipeline Drugs Product Location Distribution &nbsp;3.4.2 Players CINV Existing and Pipeline Drugs Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for CINV Existing and Pipeline Drugs by Geographic Region &nbsp;4.1 World Historic CINV Existing and Pipeline Drugs Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic CINV Existing and Pipeline Drugs Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global CINV Existing and Pipeline Drugs Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas CINV Existing and Pipeline Drugs Sales Growth &nbsp;4.4 APAC CINV Existing and Pipeline Drugs Sales Growth &nbsp;4.5 Europe CINV Existing and Pipeline Drugs Sales Growth &nbsp;4.6 Middle East & Africa CINV Existing and Pipeline Drugs Sales Growth 5 Americas &nbsp;5.1 Americas CINV Existing and Pipeline Drugs Sales by Country &nbsp;5.1.1 Americas CINV Existing and Pipeline Drugs Sales by Country (2020-2025) &nbsp;5.1.2 Americas CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) &nbsp;5.2 Americas CINV Existing and Pipeline Drugs Sales by Type (2020-2025) &nbsp;5.3 Americas CINV Existing and Pipeline Drugs Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC CINV Existing and Pipeline Drugs Sales by Region &nbsp;6.1.1 APAC CINV Existing and Pipeline Drugs Sales by Region (2020-2025) &nbsp;6.1.2 APAC CINV Existing and Pipeline Drugs Revenue by Region (2020-2025) &nbsp;6.2 APAC CINV Existing and Pipeline Drugs Sales by Type (2020-2025) &nbsp;6.3 APAC CINV Existing and Pipeline Drugs Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe CINV Existing and Pipeline Drugs by Country &nbsp;7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025) &nbsp;7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) &nbsp;7.2 Europe CINV Existing and Pipeline Drugs Sales by Type (2020-2025) &nbsp;7.3 Europe CINV Existing and Pipeline Drugs Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa CINV Existing and Pipeline Drugs by Country &nbsp;8.1.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs &nbsp;10.3 Manufacturing Process Analysis of CINV Existing and Pipeline Drugs &nbsp;10.4 Industry Chain Structure of CINV Existing and Pipeline Drugs 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 CINV Existing and Pipeline Drugs Distributors &nbsp;11.3 CINV Existing and Pipeline Drugs Customer 12 World Forecast Review for CINV Existing and Pipeline Drugs by Geographic Region &nbsp;12.1 Global CINV Existing and Pipeline Drugs Market Size Forecast by Region &nbsp;12.1.1 Global CINV Existing and Pipeline Drugs Forecast by Region (2026-2031) &nbsp;12.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global CINV Existing and Pipeline Drugs Forecast by Type (2026-2031) &nbsp;12.7 Global CINV Existing and Pipeline Drugs Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 GlaxoSmithKline &nbsp;13.1.1 GlaxoSmithKline Company Information &nbsp;13.1.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications &nbsp;13.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 GlaxoSmithKline Main Business Overview &nbsp;13.1.5 GlaxoSmithKline Latest Developments &nbsp;13.2 Helsinn &nbsp;13.2.1 Helsinn Company Information &nbsp;13.2.2 Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications &nbsp;13.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Helsinn Main Business Overview &nbsp;13.2.5 Helsinn Latest Developments &nbsp;13.3 Heron Therapeutics &nbsp;13.3.1 Heron Therapeutics Company Information &nbsp;13.3.2 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications &nbsp;13.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Heron Therapeutics Main Business Overview &nbsp;13.3.5 Heron Therapeutics Latest Developments &nbsp;13.4 Merck &nbsp;13.4.1 Merck Company Information &nbsp;13.4.2 Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications &nbsp;13.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Merck Main Business Overview &nbsp;13.4.5 Merck Latest Developments &nbsp;13.5 Tesaro &nbsp;13.5.1 Tesaro Company Information &nbsp;13.5.2 Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications &nbsp;13.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Tesaro Main Business Overview &nbsp;13.5.5 Tesaro Latest Developments 14 Research Findings and Conclusion

Report	Global CINV Existing and Pipeline Drugs Market Growth 2025-2031
Selected License	Multi ID: LPI24633

Buyer Information

Order Summary